A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

ClinicalTrials.gov ID: NCT07830732

Public ClinicalTrials.gov record NCT07830732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multinational, Open-label Study to Investigate Efficacy and Safety of Denecimig (Mim8) in Adults With Acquired Haemophilia A

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out if denecimig is safe and effective for treating people who have acquired haemophilia A. Participants will be in this study for up to around 1 year and 5 months (73 week).

Study identification

NCT ID: NCT07830732
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Haemophilia A

Interventions

Denecimig Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 9, 2026 (Estimated)
Primary completion: Mar 23, 2029 (Estimated)
Completion: Mar 23, 2029 (Estimated)
Last update posted: Sep 21, 2026

2026 – 2029

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 18

Facility	City	State	ZIP	Site status
University of Iowa_Iowa City	Iowa City	Iowa	52242	—
Tulane University School of Medicine	Metairie	Louisiana	70001	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University	St Louis	Missouri	63110	—
University of North Carolina	Chapel Hill	North Carolina	27614	—
Duke University_Durham	Durham	North Carolina	27710	—
University of Oklahoma Health	Oklahoma City	Oklahoma	73104	—
Penn State MS Hershey Med Ctr	Hershey	Pennsylvania	17033-2360	—
Univ of Pennsylvania Hospital	Philadelphia	Pennsylvania	19104	—
UT Southwestern	Dallas	Texas	75390	—
Univ Texas HSC-Houston	Houston	Texas	77030	—
UT Health San Antonio	San Antonio	Texas	78229	—
University of Utah Health	Salt Lake City	Utah	84106	—
University of Vermont Med Ctr	Burlington	Vermont	05401	—
University of Virginia	Charlottesville	Virginia	22903	—
Virginia Cwealth Univ Richmond	Richmond	Virginia	23298	—
Washington Ctr Bleed Disorder	Seattle	Washington	98195	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07830732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 21, 2026 · Synced Oct 2, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07830732 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →